Fig. 4: Metabolomic analysis of GLUD2 and its mutant in the SN of MPTP-treated mice.
From: Functional validation of a human GLUD2 variant in a murine model of Parkinson’s disease
a The relative abundances of representative metabolites in each sample are shown. b Overall metabolic profiles of samples from the AAV-GFP, MPTP + AAV-GFP, MPTP + AAV-GLUD2, and MPTP + AAV-GLUD2 T1492G groups using PCA plots. c Overview of metabolic profiles of all samples using 3-D PCA score plots. d Z-score plots showing the relative variations of each individual metabolite across all groups in the form of a heatmap. e MPEA of potential pathways involved in the differential metabolite content between the indicated groups. f The network of metabolites in the TCA cycle for MPTP + AAV-GFP versus MPTP + AAV-GLUD2 T1492G groups. Dashed boxes indicate no detection, solid boxes indicate normal expression, red boxes indicate upregulation in the MPTP + AAV-GLUD2 T1492G group compared with the MPTP + AAV-GFP group, and green boxes indicate downregulation in the MPTP + AAV-GLUD2 T1492G group compared with the MPTP + AAV-GFP group.
